• Atavistik Bio Raises $160M in Series B Funding, Including $40M Extension
Atavistik Bio - Latest News and Information
  • All Technology
  • AI
  • Autonomy
  • B2B Growth
  • Big Data
  • BioTech
  • ClimateTech
  • Consumer Tech
  • Cybersecurity
  • DevOps
  • Digital Marketing
  • Ecommerce
  • EdTech
  • Enterprise
  • FinTech
  • GovTech
  • Hardware
  • HealthTech
  • HRTech
  • LegalTech
  • Nanotech
  • PropTech
  • Quantum
  • Robotics
  • SaaS
  • SpaceTech
AllNewsDealsSocialBlogsVideosPodcastsDigests

Technology Pulse

EMAIL DIGESTS

Daily

Every morning

Weekly

Tuesday recap

Top Publishers

  • The Verge AI

    The Verge AI

    21 followers

  • TechCrunch AI

    TechCrunch AI

    19 followers

  • Crunchbase News AI

    Crunchbase News AI

    15 followers

  • TechRadar

    TechRadar

    15 followers

  • Hacker News

    Hacker News

    13 followers

See More →

Top Creators

  • Ryan Allis

    Ryan Allis

    207 followers

  • Elon Musk

    Elon Musk

    79 followers

  • Sam Altman

    Sam Altman

    68 followers

  • Mark Cuban

    Mark Cuban

    56 followers

  • Jack Dorsey

    Jack Dorsey

    39 followers

See More →

Top Companies

  • SaasRise

    SaasRise

    209 followers

  • Anthropic

    Anthropic

    40 followers

  • OpenAI

    OpenAI

    22 followers

  • Hugging Face

    Hugging Face

    15 followers

  • xAI

    xAI

    12 followers

See More →

Top Investors

  • Andreessen Horowitz

    Andreessen Horowitz

    16 followers

  • Y Combinator

    Y Combinator

    15 followers

  • Sequoia Capital

    Sequoia Capital

    12 followers

  • General Catalyst

    General Catalyst

    8 followers

  • A16Z Crypto

    A16Z Crypto

    5 followers

See More →
NewsDealsSocialBlogsVideosPodcasts
HomeAtavistik Bio
Atavistik Bio logo

Atavistik Bio

0 followers

About Atavistik Bio

Atavistik Bio is a biotechnology company focused on discovering precision allosteric therapeutics by unlocking hidden functional pockets in target proteins. The company develops a proprietary discovery approach that identifies cryptic allosteric sites and rapidly advances small molecule therapeutics with the potential for high efficacy and tolerability. Its work targets high-need areas such as precision oncology and rare diseases, with plans to expand through partnerships to other therapeutic areas. Headquartered in the United States, Atavistik Bio emphasizes translating advanced science into transformative medicines for patients.

Recent News

No recent news for this company.

Recent Deals

Atavistik Bio Raises $160M in Series B Funding, Including $40M Extension

March 31, 2026

Key Facts

HQ Location

Cambridge, United States

Founded

2021

Employees

11 - 50

Status

Private

Website

https://atavistikbio.com